Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC) -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (792)	2/10/2006 1:53:23 AM
From: Icebrg	Read Replies (1) \| Respond to of 946

No, I wouldn't say that. As you know, there was a positive result from the use of Xyotax among pre-menopausal woman in the Stellar trials. This might be the result of datamining or a true treatment effect. We don't know how many subgroups, that were pre-defined. CTIC suggests, as an explanation, that the reason for these results might be higher estrogen levels (compared to older woman and to men) in this group. The higher levels leads to a higher degree of expression of an enzyme, Cathepsin-B, which is the enzyme that cleaves the prodrug. The suggestion is, that due to the higher expression, more paclitaxel is released inside the cell leading to a better treatment result. Erik